STOCKS TELEGRAPH

Category: Featured

  • GoHealth Inc (GOCO) stock plunged in the pre-market. Here’s why

    The stock of GoHealth Inc (GOCO) closed the recent trading session at $1.45, losing 27.14% from the previous trading session. The stock of GOCO further lost 14.57% in the pre-market, to $1.7. The firm published the preluded fiscal performance for Q4 and FY21. GOCO also filed for form 4 on 15 February 2022. The form refers to the change in beneficial ownership of securities.

    GOCO’s FY21 expectations

    GoHealth Inc published the preluded fiscal performance of its Q4 and FY21 on 1 March 2022. The main points are

    • GOCO estimates the sales for Q4 of FY21 to be between $425 million and $470 million. Also, Yearly sales are estimated to be in the range of $1.04 billion and $1.08 billion.
    • The firm expects the total loss for Q4 of FY21 to be in the middle of $38.8 million and $52.7 million. While the firm estimates yearly loss to be in the range of $141 million and $155 million.
    • GOCO estimates the adjusted EBITDA to in the range of -$5.5 million and $8.5 million. Further, the annual adjusted EBITDA is estimated to be in between $26.5 million and $40.5 million.

    CEO Remarks

    The CEO of GoHealth Inc (GOCO), Clint Jones, commented that he appreciates each worker for the excellent endeavours during a difficult condition. He further added that they encountered significant tensions because of the expanded customer shopping and surprisingly high labor price.

    Further, Mr. Jones concluded that he anticipates giving more insight concerning their 2021 presentation alongside their 2022 direction. The earnings call for GOCO will be on 15 March 2022.

    About GOCO

    Gohealth Inc is an advanced wellbeing organization, which takes part in the arrangement of insurance services. The firm works in four sections: Medicare-Internal, Medicare-External, Individual and family plans Internal, and IFP External. The firm has a market cap of $638.21 million and 320.71 million pending shares. GOCO has its headquarter in Chicago, Illinois, United States of America (USA).

  • Guardion Health Sciences Inc (GHSI) stock is gaining in the pre-market. Here’s why

    The stock of Guardion Health Sciences Inc (GHSI) closed the recent trading session at $0.28, gaining 47.84% from the previous session. During the last check, the stock of GHSI remained bullish in the pre-market, gaining 49.29% to $0.418. GHSI declared the closing of its preceding public offer. The company also filed for the form SC 13G with SEC on 28 February 2022.

    Guardion Health Sciences Inc (GHSI) is a clinical nourishment and diagnostics organization. GHSI creates clinical food varieties and clinical gadgets in the visual wellbeing space and creates nutraceutical items to give steady medical advantages to clients. The organization’s clinical gadgets are utilized to quantify visual capacity and certain physical elements of the eye that recognize early sickness. The firm has a market cap of $6.83mn and 24.43mn shares pending. The firm has its headquarter in Houston, Texas, United States of America (USA).

    GHSI’s News

    On 23 February 2022, Guardion Inc declared the closing of its preceding public offering of 37 million stocks. GHSI issued warrants A and warrants B to buy up to 37 million of the normal stock. The price of the normal stock was $0.30 per stock. Further, warrant A had the price of $0.37 per stock with validity for five years from the issue date. While the warrant B had the price of $0.37 with a validity for 18 months from the issue date. Moreover, the total amount from the public offering was $11 million.

    On February 14, 2022, GHSI reported about the release of its Viactiv Omega Boost gel bites. The Omega gel bites are intended to give all out the body support, including cardiovascular, neurological, joint, and visual wellbeing. The CEO of GHSI, Bret Scholtes, stated that they are eager to have the option to offer steady supplements under the reliable Viactiv brand. He further added that they anticipate being a dependable asset for the nourishing enhancement needs of their clients.

  • Bionano Genomics Inc (BNGO) stock lost 8.8% in the after-market. Here’s why

    The stock of Bionano Genomics Inc (BNGO) closed the recent trading session at $2.16, 0.93% more than the previous trading session. On the last check, the stock of BNGO followed a bearish pattern in the after-market, losing 8.8% to $1.97. BNGO published the financial performance for its Q4 and FY21.

    BNGO’s FY21 performance

    On 1 March 2022, Bionano Genomics published the financial performance for the period Q4 and FY21, which ended on 31 December 2021. The company posted revenue of $6.3 million in Q4 of FY21 compared to $3.9 million in the corresponding period of last year. This marks a growth of 57.9%. The yearly revenue expanded by 111.4% to $17.9 million in 2021 from $8.5 million in 2020. Total loss of BNGO grew by 95.6% in Q4 of FY21 to $22.9 million versus $11.7 million in Q4 of FY20. The yearly loss expanded by 76.2% in 2021 to $72.4 million. BNGO’s operating loss increased by 158.7% in Q4 of FY21 to $28.7 million against $11.1 million in the same year-ago period. Also, the yearly operating loss expanded by 99.9% in 2021 to $77.1 million.

    The company sold 12,518 flow cells in the fiscal year 2021. The Saphyr system of the company grew by 14% to 164 bases in Q4 of FY21 versus 141 bases in Q4 of FY20. Further, BNGO finished the principal model for the single-molecule imaging framework for OGM. Moreover, Bionano obtained BioDiscovery, Inc, including its industry-driving software, NxClinical.

    CEO Remarks

    The CEO of Bionano Genomics, Erik Holmlin, stated that they accept 2021 was ground-breaking for Bionano. He further added that they added top-notch software through the addition of BioDiscovery and fundamentally improved their programming aptitude.

    Mr. Holmlin concluded that they start in 2022 hoping to proceed with the energy that is enhanced throughout 2021.

    About BNGO

    Bionano Genomics (BNGO) is a supplier of genome investigation arrangements. The investigations can empower analysts and clinicians to further uncover answers to inquiries in medication. The company has a market cap of $624.6 million and 289.18 million pending shares. BNGO have a headquarter in San Diego, California, the United States of America (USA),

  • Proterra Inc. (PTRA) Stock Sinking Deep in Aftermarket. What’s going on

    Proterra Inc. (PTRA) is a leading designer and manufacturer of zero-emission electric transit vehicles along with EV tech solutions for commercial purposes. The company’s product line is durable and energy-efficient and is based on laborious independent testing.

    The price of PTRA stock during the regular trading on March 1, 2022, was $8.23 with a deceleration of 8.96%. At last check in the aftermarket, the stock dropped further by 12.7%.

    PTRA: Key Financials

    On March 01, 2022, PTRA released its consolidated financial results for the fourth quarter of 2021 ended December 31, 2021. Some of the key aspects are discussed here.

    Revenue

    Total revenue in Q4 2021 was $68.4 million versus $54.1 million for the same quarter of 2020. The company observed an increment of $14.2 million in its revenue year-over-year. Also, the company missed the revenue expectations of $71.1 million.

    EPS

    Diluted net loss per share in the fourth quarter of 2021 was $45.1 million or $0.43 in comparison to $32.6 million or $6.38 for the same quarter of 2020. The company observed a noteworthy incline in its EPS year-over-year. Also, it missed the EPS estimates of -$0.18.

    PTRA: Events and Happenings

    On January 27, 2022, PTRA reported that The Santa Clara Valley Transportation Authority will install a novel clean energy microgrid and electric vehicle fleet charging platform with PTRA and Scale Microgrid Solutions. It will support the agency’s evolution to a full zero-emission bus fleet and the grant was awarded by the California Energy Commission for the project.

    On January 18, 2022, PTRA and Nikola Corp. announced a supply deal for multiple years to support Nikola’s zero-emission semi-trucks with the company’s leading battery technology. On January 13, 2022, PTRA and Vicinity Motor Corp. updated on their strategic partnership to support Vicinity’s work trucks and electric transit buses with the company’s battery technology.

    On December 14, 2021, PTRA informed about its plan to open an EV battery system production plant to manufacture its battery systems for clients in South Carolina.

    Conclusion

    Due to the economic crisis during the last year, PTRA stock was 61% down in that period. The current stock situation of the company is debilitating as it dipped in regular trading as well as aftermarket. It is the impact of the current fourth-quarter financial statement release as the company missed both revenue and EPS targets.

  • Selinexor Regulatory Update: Karyopharm Therapeutics Inc. (KPTI) Collapse After Hours

    On March 01, Karyopharm Therapeutics Inc. (KPTI) provided U.S. regulatory updates on Selinexor in advanced or recurrent endometrial cancer. Consequently, the stock suffered a huge blow and collapsed in the after-hours on Tuesday.

    During the regular trading session, KPTI stock varied between a high of $10.71 and a low of $10.20. The stock closed the session in the green with a small gain of 0.58% as 2.74 million shares exchanged hands. Thus, at the close of the regular trading session, KPTI had a value of $10.39 per share. Following the announcement, the stock collapsed in the after-hours to reach $7.69. Hence, the stock suffered a loss of 25.99% or $2.70 in the after-hours on Tuesday.

    The commercial-stage pharmaceutical company, Karyopharm Therapeutics Inc. has a market capitalization of $782.46 million. Currently, the company has 75.75 million shares outstanding in the market. So far 2022 has proved a very fruitful year for the stock as it has increased by 61.59% year to date, while it lost 21.23% last year.

    KPTI’s Regulatory Update

    The company has been in discussions with the FDA regarding a supplemental New Drug Application (sNDA) of selinexor. The company had previously planned the sNDA submission on Phase 2 SIENDO study data. The SIENDO study is assessing selinexor as front-line maintenance therapy after chemotherapy in advanced or recurrent endometrial cancer patients.

    Source: Global Regulatory Partners

    Recently, the company had a productive meeting regarding the submission with the FDA. As per the feedback, the FDA has deemed the current top-line results of SIENDO study as unlikely to support sNDA approval. The company and FDA had differing views regarding the matter and further exploration of advanced or recurrent endometrial cancer with p53 wild-type was discussed.

    KPTI is further analyzing the SEINDO study data and plans to work with the FDA for exploring all regulatory pathways. Moreover, the company plans to commence a new clinical study in p53 wild-type endometrial cancer patients with data expected in H1 2024.

    Inducement Grants

    On February 28, the company announced granting stock options of purchasing 168,500 common shares and 112,200 restricted stock units to nine new employees. The equity awards were granted as inducement material to the employees under its 2022 Inducement Stock Incentive Plan.

    KPTI’s Financials

    As reported, KPTI’s net product revenue increased by 47% YOY to $29.8 million in the fourth quarter of 2021.

    Furthermore, the company had a net income of $38.7 million or $0.46 on a diluted share basis in Q4 2021. Comparatively, the company had a net loss of $43.4 million or $0.59 per share in Q4 2020.

  • Inovio Pharmaceuticals Inc (INO) stock nosedived in the after-hours. Here’s why

    The stock of Inovio Pharmaceuticals Inc (INO) nosedived in the after-market, following the announcement of financial performance for Q4 and FY21. INO stock lost 12.35% in the after-hours, to $2.84. The stock of INO closed the recent trading session at $3.24, with no change from the previous trading session. Inovia also filed the forms 10-K, 4, and S-8 with SEC on 1 March 2022.

    Inovia Pharmaceuticals Inc is a biotechnology organization centered around the disclosure, production, and commercialization of manufactured DNA items for treating malignant growths and infections. The company has a market capitalization of $681.6 million with 210.39 million pending shares. INO has its headquarter in San Diego, California, United States of America (USA).

    INO’s FY21 highlights

    Inovia declared the financial performance for its Q4 and FY21, on 1 March 2022. The financial highlights for Q4 and FY21 are

    • INO’s revenue reduced by 76% to $1.7 million in 2021 versus $7.4 million in 2020. The Q4 revenue for FY21 was $0.8 million compared to $5.6 million in Q4 of FY20.
    • The company reported a loss of $106.9 million in Q4 of FY21 versus $24.3 million in Q4 of FY20. The yearly loss expanded by 81.3% to $303.6 million in 2021 compared to $167.4 million in 2020.
    • Moreover, the loss of $0.50 and $1.45 per stock in Q4 and FY21, respectively.
    • Cash and cash equivalents of the company were reduced by 71.6% to $71.1 million in 2021 from $250.7 million in 2022.

    CEO Remarks

    The CEO of Inovio Pharmaceuticals (INO), DR J. Joseph Kim, commented that COVID-19 addresses a  constant danger to the wellbeing of the community worldwide. He added that compared to their COVID-19 struggles, they are happy with the clinical progress of their DNA-based medications.

    DR Kim concluded that they have finished enlistment in a Phase 1b preliminary for Lassa fever. Also, a Phase 1b preliminary for an Ebola vaccine, as well as a Phase 2 preliminary for Middle East Respiratory Syndrome (MERS).

  • Ra Medical Systems Inc. (RMED) stock Falls Under Corrections After Hours

    On February 28, Ra Medical Systems Inc. (RMED) announced to have filed a 510(k) application for its DABRA Catheter with the FDA. Consequently, the stock added 17.02% in the following market session on March 01. The gain called for-profit booking and corrections in the after-hours on Tuesday.

    The news resulted in investors flocking towards the stock on Tuesday as its volume reached 85.47 million. During the regular session, RMED stock was able to add a value of $0.07 or 17.02%. The stock closed the session at a price of $0.50 per share. Subsequently, the stock fell under corrections in the after-hours to lose 4.96%. Hence, the stock was trading at a value of $0.48 per share in the after-hours on Tuesday.

    The dermatologic and cardiovascular diseases excimer lasers developer, Ra Medical Systems Inc. was founded in 2002. The company has a market capitalization of $11.24 million with 26.33 million shares outstanding.

    RMED stock Analysis

    While Tuesday’s regular session gains were enough to call for profit booking, the stock had been in an uptrend for the past few days. Thus, RMED stock was bound to fall under corrections with the extended gains on Tuesday. Therefore, the stock succumbed to corrections in the after-hours as it had added 40.00% in the past five days.

    The uptrend of the stock before the news seemed to have been due to the recent downfall of the stock. With the apparent crash of the stock market due to the Russia-Ukraine conflict, RMED also declined to its new low on February 24. Following this, the stock rebounded as investors started buying the stock due to the low price.

    510(k) Application Filing

    As per Monday’s announcement, RMED submitted the 510(k) for its DABRA catheter with a braided over jacket and six-month shelf life. The application was filed for the catheter as a device for crossing chronic total occlusions in symptomatic infrainguinal lower extremity vascular disease patients. It also includes an intended use for ablating a channel in occlusive peripheral vascular disease.

    Source: RegDesk

    This marks a significant step achievement in the company’s flagship commercial DABRA catheter.

    The company manufactures the DABRA excimer laser and catheters in an ISO 13485 vertically integrated facility.

    RMED’s Financial Summary

    In Q3 2021, the company reported net revenue of $5000 from continuing operations and $0.5 million from discontinued operations.

    Furthermore, RMED had $7.4 million in loss from continued operations and $0.4 million from discontinued operations in the quarter.

  • Exicure Inc. (XCUR) stock Continues on a Bullish Path After hours. Why?

    On March 01, 2022, shares of Exicure Inc. (XCUR) stock continued to rise in the after hours. The company reported no official announcement or SEC filing recently that can be attributed to the uptrend.

    The stock remained bullish with a gain of 4.79% at a volume of 16.58 million shares in regular trading. Investors flocked towards the stock on Tuesday, as the day’s volume was 175% of its 65-day average. XCUR stock traded between $0.1970 and $0.2170 to close the session at a value of $0.2099 per share. Following the close of regular trading, the stock reached $0.2700 in the after-hours, continuing its bullish path. Hence, XCUR stock added a further 28.63% at an active after-hours volume of 8.56 million shares, on Tuesday.

    The Spherical Nucleic Acid-based therapeutic developer, Exicure Inc. was founded in 2011. Currently, its 108.78 million outstanding shares trade at a market capitalization of $21.79 million.

    What is Happening with XCUR?

    Amid the Russian-Ukraine conflict, the stock nosedived to its 52-week low of $0.1360 on February 24 like most. The stock had since been in a mild uptrend. While the new low in the stock was reason enough for the stock rebound, the company also filed an SC 13D/A with the SEC on February 25. While gaining mildly for a number of days, the stock’s bullishness escalated in the after-hours on Tuesday. With no official reason, the stock seems to be gaining on external factors.

    Source: Sutterstock

    In the past five days, XCUR stock has added a good 22.61% while increasing by a mere 3.86% year to date. Moreover, the stock suffered a huge decline of 90.75% in the past year.

    Leadership transition & Board Changes

    On February 04, the company announced certain changes in its leadership and board of directors.

    Resignations

    The company’s then-President and CEO, Brian C. Bock submitted his resignation in order to pursue other opportunities. Upon his resignation, Mr. Bock will serve as a Special Advisor to the CEO during the transition period while remaining in an advisory role to the company.

    Moreover, Timothy P. Walbert, Bosun Hau, and Ander Sassine also tendered their resignations from their positions at XCUR’s board.

    Appointments

    In addition, the company also announced the appointment of certain new members. Dr. Matthias Schroff was appointed as the President and CEO and replaced Mr. Bock on the board.

    Furthermore, Dr. Elizabeth (Betsy) Garofalo was appointed as the Chair of the board and succeeded Mr. Walbert.

  • First Solar, Inc. (FSLR) Stock Dived After Hours Following Financials Release.

    First Solar, Inc. (FSLR) is a leader in solar technology along with providing responsibly-produced eco-efficient solar modules internationally for progressing the climate change fight. Its thin-film photovoltaic modules characterize the next-generation solar technologies, thus providing a low-carbon substitute to crystalline silicon PV panels.

    The price of FSLR stock during the regular trading on March 1, 2022, was $75.6 with a slight gain of 0.44%. at last check in the aftermarket, the stock nose-dived by 15.6%.

    FSLR: Key Financials

    On March 01, 2022, FSLR released its financial statement for the fourth quarter of 2021 ended December 31, 2021. Some of the important points are discussed below.

    Net Sales

    Net sales in Q4 2021 were $0.9 billion as compared to $0.6 billion in the same period of 2020. The company observed an increase of $0.3 billion in its net sales over the year. Also, it missed the analyst’s expectations of the revenue of $924 million.

    EPS

    Diluted net income per share in the fourth quarter of 2021 was $0.13 billion or $1.23 compared to $45.2 million or $1.08 in the same quarter of a year ago. The company observed a significant increase in its EPS over the year. Also, the company topped the EPS estimates of $1.08.

    FSLR: Events and Happenings

    On January 13, 2022, FSLR reported the placement of an order from Swift Current Energy for 1.2 gigawatts of advanced, ultra-low thin-film PV modules. The modules will be delivered by 2023-2024. On December 17, 2021, Prairie Wolf Solar Project, which uses FSLR’s Series 6 thin-film solar modules, its commercial operation was initiated by National Grid Renewables. The MISO located project claims 200 megawatts of clean solar power.

    ON November 22, 2021, FSLR updated on the placement of multiple-year orders by the leading companies including Lightsource bp and bp. for approximately 5.4 gigawatts of its thin-film PV modules. As part of the contract, both the companies had placed firm orders for up to 4.4GW of the modules, with options for supplementary 1GW.

    Conclusion

    FSLR stock is 20% short the past six months as the company down-performed in the pandemic period. The recent aftermarket stock drop is the outcome of the company’s financial statement release which missed the revenue target but topped the EPS estimates.

  • ContextLogic Inc. (WISH) Stock Tumbling in Aftermarket Following Financial Results Announcement.

    ContextLogic Inc. (WISH) brings an entertainment-filled and affordable shopping experience to customers globally. It is the one of largest international e-commerce portfolios, connecting loads of value-conscious customers to approximately half-million merchants. globally. The company merges the technology and data science capacities and a novel discovery-based mobile shopping experience.

    The price of WISH stock during the regular trading on March 1, 2022, was $2.27 with a drop of 4.22%. at last check in the aftermarket, the stock dipped further by 6.17%.

    WISH: Key Financials

    On March 01, 2022, WISH released its unaudited financial outcomes for Q4 2021 ended December 31, 2021. Some of the vital points are discussed below.

    Revenue

    Revenues in the fourth quarter of 2021 were $289 million compared to $794 million for the same quarter in 2020. The company observed a decrease of 64% in its revenue year-over-year. Also, the company missed the analyst’s revenue expectations of $309.8 million.

    EPS

    Basic and diluted net loss in Q4 2021 was $58 million or $0.09 per share compared to $569 million or $3.04 per share for the same period of 2020. The company observed a noteworthy increase in its EPS over the year. Also, it topped the EPS estimates of -$0.10.

    WISH: Events and Happenings

    On February 15, 2022, WISH introduced the Wish Clips, which is a shoppable video feature designed to enhance the consumer’s experience and streamline the purchase path. On February 2, 2022, WISH introduced an ‘invite-only’ merchant choice procedure. The new merchants who want to sign up to sell their products on the company’s marketplace will participate in a multi-step qualification procedure.

    On February 1, 2022, WISH reported the award of the grant of inducement to its CEO, Vijay Talwar, as required by Nasdaq Listing Rule. The award was granted under the company’s New Employee Equity Incentive Plan. On December 16, 2021, WISH updated on the partnership with Nasdaq for fixing a co-branded vending machine shopping experience at 4 Times Square.

    Conclusion

    WISH stock downplayed by 87% in the last year as the pandemic hit the economy hard. The current stock position of the company is not much good as it declined in Tuesday’s aftermarket following the financial statement release. The company topped the EPS estimates but missed the revenue goal.